Acurx Pharmaceuticals, Inc. — fact timeline

Acurx Pharmaceuticals, Inc. entered into Securities Purchase Agreement with the investors named therein (the "Investors") valued at aggregate gross proceeds of approximately $2.5 million (effective 2026-04-15).

“On April 15, 2026, Acurx Pharmaceuticals, Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with the investors named therein (the “Investors”), pursuant to which the Company agreed to issue and sell, in a registered direct offering by the Company directly to the Investors (the “Registered Offering”) (i) 816,068 shares (the “Shares”) of common stock, par value $0.001 per share, of the Company (the “Common Stock”) at a purchase price of $3.03 per share and (ii) pre-funded common stock purchase warrants (the “Pre-Funded Warrants”) to purchase up to 9,017 shares of Common Stock (the “Pre-Funded Warrant Shares”) at a purchase price of $3.029 per share for aggregate gross proceeds of approximately $2.5 million”

Acurx Pharmaceuticals, Inc.: Amendment to Certificate of Incorporation to increase authorized shares of common stock from 200,000,000 to 250,000,000 (effective 2025-09-22).

“the Company’s stockholders approved an amendment (the “Amendment”) to the Company’s Certificate of Incorporation, as amended, to increase the total number of authorized shares of the Company’s common stock from 200,000,000 to 250,000,000. On September 22, 2025, the Company filed the Amendment with the Secretary of State of the State of Delaware with immediate effect.”

Acurx Pharmaceuticals, Inc.: Filing of certificate of amendment to effect a 1-for-20 reverse stock split of common stock, effective August 4, 2025 at 4:01 p.m. Eastern Time (effective 2025-08-04).

“On July 31, 2025, Acurx Pharmaceuticals, Inc. (the “Company”) filed with the Secretary of State of the State of Delaware an amendment (the “Certificate of Amendment”) to its certificate of incorporation to effect a reverse stock split of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at a ratio of 1-for-20 (the “Reverse Stock Split”).”

Acurx Pharmaceuticals, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“March 25, 2025, Acurx Pharmaceuticals, Inc. (the “Company”) received a letter from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market (the “Notice”) based on the information provided in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024. Nasdaq Listing Rule 5550(b)(1) requires that companies listed on The Nasdaq Capital Market with a market value of listed securities of less”

Acurx Pharmaceuticals, Inc. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“February 24, 2025, Acurx Pharmaceuticals, Inc. (the “Company”) received a letter from The Nasdaq Stock Market (“Nasdaq”) notifying the Company that for the preceding 31 consecutive business days the Company’s common stock did not maintain a minimum closing bid price of $1.00 per share as required by Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The notice has no immediate effect on the listing or trading of the Company’s common stock, and the common stock will continue to trade on The Nasdaq Capital Market under the symbol “ACXP” at this time. In accordance with Nasdaq”

Acurx Pharmaceuticals, Inc. reported the first quarter ended March 31, 2024 results: net income $4.4 million or $0.28 per diluted share, EPS $0.28 per diluted share.

“The Company reported a net loss of $4.4 million or $0.28 per diluted share for the three months ended March 31, 2024”

Acurx Pharmaceuticals, Inc. reported the year ended December 31, 2023 results: net income $14.6.

“oss of $3.3 million or $0.28 per diluted share for the three months ended December 31, 2022, and a net loss of $14.6”

Acurx Pharmaceuticals, Inc. reported the three months ended December 31, 2023 results: net income $5.1 million, EPS $0.37 per diluted share.

“The Company reported a net loss of $5.1 million or $0.37 per diluted share for the three months ended December 31, 2023 compared to a net loss of $3.3 million or $0.28 per diluted share for the three months ended December 31, 2022”

Acurx Pharmaceuticals, Inc. entered into Sales Agreement with A.G.P./Alliance Global Partners valued at up to $17.0 million (effective 2023-11-15).

“On November 15, 2023, Acurx Pharmaceuticals, Inc. (the “Company”) entered into a sales agreement (the “Sales Agreement” and such transactions contemplated thereby, the “ATM Program”) with A.G.P./Alliance Global Partners (the “Sales Agent”), pursuant to which the Company may offer and sell, from time to time, shares (the “Shares”) of its common stock, par value $0.001 per share (the “Common Stock”), having an aggregate offering price of up to $17.0 million through the Sales Agent, acting as agent.”

Acurx Pharmaceuticals, Inc. reported third quarter ended September 30, 2023 results: net income $3.1 million or $0.24 per diluted share.

“The Company reported a net loss of $3.1 million or $0.24 per diluted share for the three months ended September 30, 2023”

Acurx Pharmaceuticals, Inc. reported the second quarter ended June 30, 2023 results: net income a net loss of $3.4 million or $0.28 per diluted share, EPS $0.28 per diluted share.

“The Company reported a net loss of $3.4 million or $0.28 per diluted share for the three months ended June 30, 2023, compared to a net loss of $2.6 million or $0.26 per diluted share for the three months ended June 30, 2022”

Acurx Pharmaceuticals, Inc.: Amendment to Certificate of Incorporation to reflect new Delaware law provisions regarding officer exculpation approved by stockholders and filed with Delaware Secretary of State (effective 2023-06-20).

“At the Annual Meeting of Acurx Pharmaceuticals, Inc. (“we”, “us” and “our”) held on June 15, 2023 (the “Annual Meeting”), our stockholders approved an amendment to our Certificate of Incorporation, as described in Proposal 3 of our definitive Proxy Statement filed with the Securities and Exchange Commission on April 27, 2023 (the “Proxy Statement”), and which had previously been approved by our Board of Directors subject to stockholder approval. On June 20, 2023, we filed with the Secretary of State of the State of Delaware a Certificate of Amendment of Certificate of Incorporation, the form of which was included as Appendix A to the definitive Proxy Statement.”

Acurx Pharmaceuticals, Inc. shareholders approved Amendment to Certificate of Incorporation regarding officer exculpation under Delaware law.

“Proposal 3 - Amendment to Our Certificate of Incorporation to Reflect New Delaware Law Provisions Regarding Officer Exculpation The amendment of our Certificate of Incorporation to reflect new Delaware law provisions regarding officer exculpation was approved by an affirmative vote of a majority of the shares of common stock outstanding and entitled to vote at the Annual Meeting by the following votes: Shares Voted For Shares Voted Against Abstentions Broker Non-Votes 6,054,547 81,822 31,430 2,930,682”

Acurx Pharmaceuticals, Inc. shareholders approved Ratification of CohnReznick LLP as independent auditors for fiscal year 2023 at the 2023-12-31 meeting.

“Proposal 2 - Ratification of Independent Registered Public Accounting Firm Our stockholders ratified the appointment of CohnReznick LLP as our independent auditors for the fiscal year ending December 31, 2023 by the following votes: Shares Voted For Shares Voted Against Abstentions Broker Non-Votes 9,016,668 17,184 64,629 -”

Acurx Pharmaceuticals, Inc. shareholders approved Election of Class II Directors.

“Proposal 1 - Election of Directors Our stockholders elected the following directors as Class II directors to hold office until the 2026 Annual Meeting of stockholders by the following votes: Nominees Shares Voted For Shares Withheld Broker Non-Votes David P. Luci 5,749,190 418,609 2,930,682 Jack H. Dean 5,575,112 592,687 2,930,682”

Acurx Pharmaceuticals, Inc. entered into Placement Agent Agreement with Maxim Group LLC (effective 2022-05-16).

“On May 16, 2022, the Company entered into a placement agency agreement (the “Placement Agent Agreement”) with Maxim Group LLC (the “Placement Agent”) pursuant to which the Company engaged Maxim as the placement agent in connection with the Offerings.”

Acurx Pharmaceuticals, Inc. amended Warrant Amendment Agreement with the Investor.

“In connection with the Offerings, the Company also entered into a warrant amendment agreement (the “Warrant Amendment Agreement”) with the Investor.”

Acurx Pharmaceuticals, Inc. entered into Securities Purchase Agreement with a single healthcare-focused U.S. institutional investor named therein (the "Investor") valued at approximately $4.0 million (effective 2023-05-16).

“On May 16, 2023, Acurx Pharmaceuticals, Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with a single healthcare-focused U.S. institutional investor named therein (the “Investor”), pursuant to which the Company agreed to issue and sell, in a registered direct offering by the Company directly to the Investor (the “Registered Offering”), (i) an aggregate of 601,851 shares (the “Shares”) of common stock, par value $0.001 per share, of the Company (“Common Stock”), at an offering price of $3.00 per share and (ii) an aggregate of 731,482 pre-funded warrants exercisable for shares of Common Stock (the “Pre-Funded Warrants”) at an offering price of $2.9999 per Pre-Funded Warrant, for aggregate gross proceeds from the Registered Offering of approximately $4.0 million before deducting the placement agent fee and related offering expenses.”

Acurx Pharmaceuticals, Inc. reported the nine months ended September 30, 2022 results: net income net loss of $8.8 million, EPS $0.84 per share.

“a net loss of $8.8 million or $0.84 per share for the nine months ended September 30, 2022”

Acurx Pharmaceuticals, Inc. reported the quarter ended September 30, 2022 results: net income net loss of $3.5 million, EPS $0.32 per diluted share.

“The Company reported a net loss of $3.5 million or $0.32 per diluted share for the three months ended September 30, 2022”